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Innovative intelligent insole system reduces diabetic foot 
ulcer recurrence at plantar sites: a prospective, randomised, 
proof-of-concept study
Caroline A Abbott, Katie E Chatwin, Philip Foden, Ahmad N Hasan, Chandbi Sange, Satyan M Rajbhandari, Prabhav N Reddy, Loretta Vileikyte, 
Frank L Bowling, Andrew J M Boulton, Neil D Reeves
Summary
Background Prevention of diabetic foot ulcer recurrence in high risk patients, using current standard of care methods, 
remains a challenge. We hypothesised that an innovative intelligent insole system would be effective in reducing 
diabetic foot ulcer recurrence in such patients.
Methods In this prospective, randomised, proof-of-concept study, patients with diabetes, and with peripheral 
neuropathy and a recent history of plantar foot ulceration were recruited from two multidisciplinary outpatient 
diabetic foot clinics in the UK, and were randomly assigned to either intervention or control. All patients received an 
insole system, which measured plantar pressure continuously during daily life. The intervention group received 
audiovisual alerts via a smartwatch linked to the insole system and offloading instructions when aberrant pressures 
were detected; the control group did not receive any alerts. The primary outcome was plantar foot ulcer occurrence 
within 18 months. This trial is registered with ISRCTN, ISRCTN05585501, and is closed to accrual and complete.
Findings Between March 18, 2014, and Dec 20, 2016, 90 patients were recruited and consented to the study, and 
58 completed the study. At follow-up, ten ulcers from 8638 person-days were recorded in the control group and four 
ulcers from 11 835 person-days in the intervention group: a 71% reduction in ulcer incidence in the intervention group 
compared with the control group (incidence rate ratio 0∙29, 95% CI, 0∙09–0∙93; p=0∙037). The number of patients 
who ulcerated was similar between groups (six of 26 [control group] vs four of 32 [intervention group]; p=0∙29); 
however, individual plantar sites ulcerated more often in the control group (ten of 416) than in the intervention group 
(four of 512; p=0∙047). In an exploratory analysis of good compliers (n=40), ulcer incidence was reduced by 86% in the 
intervention group versus control group (incidence rate ratio 0∙14, 95% CI 0∙03–0∙63; p=0∙011). In the exploratory 
analysis, plantar callus severity (change from baseline to 6 months) was greater in re-ulcerating patients (6∙5, 
IQR 4·0–8∙3) than non-re-ulcerating patients (2·0, 0·0–4∙8; p=0∙040).
Interpretation To our knowledge, this study is the first to show that continuous plantar pressure monitoring and 
dynamic offloading guidance, provided by an innovative intelligent insole system, can lead to a reduction in diabetic 
foot ulcer site recurrence.
Funding Diabetes UK and Orpyx Medical Technologies.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Lower extremity complications, including diabetic foot 
ulcers and lower limb amputations, are among the most 
common and costly complications of diabetes, comprising 
up to one-third of the direct cost of diabetes care. Over the 
course of their disease, 25% of people with diabetes will 
develop a diabetic foot ulcer, the leading cause of diabetes-
related admission to hospital; furthermore, one in five 
ulcers will result in amputation of the lower limb.1,2 Known 
clinical risk factors for diabetic foot ulcers include history 
of diabetic foot ulcer, diabetic peripheral neuropathy, foot 
deformities, and elevated plantar pressures,3–5 yet effective 
measures for the prevention of first and recurrent diabetic 
foot ulcers remain elusive. Once a person develops a foot 
ulcer, their chance of recurrence is 40% in the first year, 
rising to almost 100% over 10 years.2 Sustainable and cost-
effective management of the diabetic foot therefore lies in 
a prevention-based approach to ensure diabetic foot ulcer 
remission.2
The current standard of care for diabetic foot ulcer 
prevention includes screening for the high-risk insensate 
foot, regular footcare, use of standard therapeutic shoes 
and prescription insoles to accommodate foot deformities 
and offload high plantar pressures, and diabetic foot 
education.2 Evidence for the effectiveness of therapeutic 
footwear on diabetic foot ulcer prevention has 
inconsistencies, largely because of the absence of 
standardisation of interventions and control conditions 
in randomised controlled trials.6–8 However, sufficient, 
good-quality evidence exists in support of the use of 
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custom-made footwear with shown plantar pressure 
relief to prevent diabetic foot ulcer recurrence.6,9,10 Good 
adherence to daily wearing of such therapeutic footwear 
is required for this effectiveness.6 Technologies that alert 
the patient to their periods of high-risk plantar pressure 
during daily activities, thus empowering them to actively 
offload during these periods, could be a beneficial 
diabetic foot ulcer prevention strategy.
Diabetic foot ulcer development is intimately linked to 
high plantar pressures that develop during gait.11,12 
Reasons for increased plantar pressures, particularly in 
the forefoot, are multifactorial. For example, diabetic 
peripheral neuropathy restricts the ability to detect 
abnormally high cumulative plantar loading and alter 
walking patterns to offload;12 foot deformities1 and 
reduced ankle dorsiflexion contribute to increased 
loading of the forefoot during gait;13 and reduced plantar 
tissue thickness increases forefoot loading and reduced 
natural cushioning.14 The culminating increased plantar 
pressures can either overwhelm the ability of the soft 
plantar tissue to respond to repeated mechanical stress, 
and therefore causing damage, or occlude local capillary 
flow, both of which increase diabetic foot ulcer risk.15
Historically, the majority of diabetic foot ulcer risk 
studies to assess the role of dynamic plantar pressure 
have been designed to capture the highest peak plantar 
pressures and pressure time integrals developed during 
gait in a laboratory setting, requiring a high sample 
frequency measurement (>50 Hz).8,16,17 However, studies18,19 
done in the past 2 years show that time exceeding capillary 
pressure occlusion threshold, or static pressure (ie, a 
prolonged period of sustained plantar pressure for 
example during sitting or standing >15 min) is also an 
important variable used to quantify foot pressures and, 
therefore, potentially diabetic foot ulcer risk, which can 
be sampled at a lower frequency (8 Hz) for longer periods 
than can be measured in the laboratory setting. We have 
used measurement of static pressure to focus on 
sustained levels of high, but not peak, pressures over 
many months, during daily life activities. On the basis of 
the available evidence from pressure-related diabetic foot 
ulcer studies and cross-sectional data,6,9,10,20 we hypothesise 
that relatively low-pressure thresholds (ie, <35 mm Hg) 
might be routinely exceeded for a sustained period of 
time during some daily activities (such as sitting or 
standing) and might increase the risk of recurrence of 
diabetic foot ulcer. This hypothesis is further supported 
by the fact that even relatively low external plantar 
pressures (<35 mm Hg) occlude capillary bed perfusion 
in the soft tissues of the foot,21 and patients with diabetic 
foot ulcer have significantly impaired neurovascular 
response to pressure compared with those without 
diabetic foot ulcer.15
Patients with diabetic peripheral neuropathy can be 
trained to alter their gait and effectively offload pressure 
after feedback,16,17,22 as has been shown in studies using 
Research in context
Evidence before this study
We searched PubMed, MEDLINE, and all available systematic 
reviews and meta-analyses across all possible publication years, 
using the major search terms, “diabetic foot”, “diabetic foot 
ulcer”, “diabetic foot ulcer recurrence”, “diabetic foot ulcer 
prevention”, “foot ulcer prevention”, “diabetic foot pressure”, 
“foot pressure diabetes”, “foot pressure diabetes”, “foot 
pressure feedback diabetes”, “diabetic foot pressure feedback”, 
“diabetic foot ulcer technology”. No language restrictions were 
used. All studies were included and considered regardless of 
quality threshold.
Previous research into diabetic foot ulcer prevention has focused 
on the use of passive offloading through therapeutic footwear 
and custom-made orthotics (ie, passive solutions, because there 
is no active element to sense and adapt to changing conditions) 
for accommodating foot deformities and reducing high plantar 
pressures. A body of evidence from laboratory-based studies 
measuring foot pressures during walking in people with diabetes 
shows the association between high foot pressures and elevated 
risk of plantar ulceration. Two laboratory-based case studies 
suggest pressure feedback as a means of reducing plantar 
pressures, and thus potentially reducing the risk of development 
of foot ulcer. To date, foot pressure feedback has not been used as 
an intervention in people with diabetes throughout daily life for 
reducing foot ulcer recurrence.
Added value of this study
To our knowledge, this is the first prospective, randomised, 
proof-of-concept study to investigate the effectiveness of an 
intelligent insole system (designed to measure static plantar 
pressure continuously during daily life activities and guide 
regular self-directed, dynamic offloading) in preventing diabetic 
foot ulcers in people with diabetes at high risk of ulcer 
development and a recent history of a healed diabetic foot ulcer. 
Although previous studies on diabetic foot ulcer prevention have 
shown mixed efficacy using passive solutions, this study is, to our 
knowledge, the first to report how an intervention involving 
active feedback element (via a smartwatch) senses and enables 
self-directed adjustment according to the conditions 
experienced by the foot, thus reducing foot ulcer recurrence.
Implications of all the available evidence
Our study shows foot pressure might be able to be used as a 
feedback signal to compensate for the loss of sensation because 
of diabetic peripheral neuropathy and help to prevent foot ulcer 
recurrence. Providing people with diabetes with knowledge of 
their foot pressures will likely empower and enable them to have 
more control over their foot health. The wider implications of 
this study raise the possibility of using a range of active 
technologies to sense and adjust to the condition of the diabetic 
foot, enabling action by the patient to modify risk.
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portable systems that trigger alarms when patients 
exceeded a given plantar threshold, and studies using 
biofeedback training techniques.16,17 These studies were 
small, laboratory-based, and did not assess occurrence of 
diabetic foot ulcers.
We aimed to investigate the effect of an active insole 
system for its effectiveness in preventing diabetic foot 
ulcer recurrence in a real-life situation, over many 
months. This system was designed to be worn beneath 
prescription insoles of the high-risk diabetic patient and 
used to continuously measure plantar pressure during 
daily life over many months, providing feedback when 
sustained, low-magnitude plantar pressure occurs during 
harmful physical activities, such as prolonged sitting or 
standing, to guide regular offloading.
Methods
Study design and patients
In this prospective, randomised, single-blinded (patient 
only), proof-of-concept study, patients were recruited 
from two multidisciplinary outpatient diabetic foot clinics 
in the UK. The study was approved by local research 
ethics committees and other relevant governance bodies 
in the UK, and the protocol is available in the appendix.
Major inclusion criteria were age at least 18 years, 
type 1 or type 2 diabetes, history of previous ulceration on 
the weight-bearing surfaces of the foot, presence of diabetic 
peripheral neuropathy (as defined by any loss of sensation), 
and ability to walk independently for 30 steps. Major 
exclusion criteria were active foot ulceration; severe 
vascular disease; lower limb amputation above the level of 
the ankle; in-shoe orthotics consisting of non-compressible 
materials; dementia, uncorrected visual or psychological 
impairment; psychiatric illnesses or social situations 
limiting compliance with the study; inner ear pathology or 
other serious underlying balance dysfunction; significant 
cardiopulmonary or other systemic disease limiting the 
patient’s ability to walk approximately 30 steps; current 
participation in another clinical investigation of a medical 
device or a drug; or body-mass index (BMI) of more than 
40 kg/m². All patients provided written informed consent 
before enrolment.
Randomisation and masking
Each site used a simple randomisation procedure based on 
a single sequence of random positive and negative 
numbers generated in a spreadsheet. At the end of the 
screening visit, patients who passed screening were 
allocated to either the intervention group (if the next 
number in the list was below or equal to 0·5) or control 
group (if the next number in the list was above 0·5). Only 
the researcher at each site knew the group allocation 
(single blinded). Podiatry assessment and treatment of all 
patients throughout the study was done by in-house 
podiatrists and clinicians who remained masked to the 
intervention. Patients completed the study after the 
18-month follow-up, at any time before the 18-month 
follow-up because of reasons other than a plantar ulcer, or 
plantar ulcer occurrence (whichever came first). A foot 
ulcer was defined as a full-thickness loss of epidermis and 
dermis or involvement of deeper structures, to at least 
Texas classification stage 1,23 on the weight-bearing surface 
of the foot. FootSnap,24 a standardised application, was 
used to acquire plantar foot photographs, which were then 
assessed by two independent, masked experts to verify 
plantar ulceration. Following ulcer verification, patients 
were removed from the study and treated appropriately 
for ulcer healing.
Procedures
Throughout the study, all patients received masked 
standard clinical care, including podiatry assessment and 
treatment. All patients wore an innovative plantar pressure-
measuring insole system in their footwear, throughout 
their day-to-day life, for the duration of the study 
(SurroSense Rx, Orpyx Medical Technologies, Canada; 
figure 1). Footwear was either off-the-shelf or custom-
made, depending on the patients’ individual podiatric 
requirements; however, lace-up or velcro shoes were 
mandatory to allow attachment of the sensor pod to the 
shoe exterior. 0∙6 mm flexible, pressure-sensing inserts 
were placed underneath the patient’s orthotics or insoles, 
and the connected sensor pod was attached to the shoe 
laces or velcro strap. Together, the sensor pod and pressure-
sensing insert weighed approximately 45 g. Each insert 
comprised eight pressure sensors located along the plantar 
surface of the foot (figure 1), recording plantar pressure at 
a sampling rate of 8 Hz. For a 2-week familiarisation and 
training period, both intervention group and control group 
patients used the intelligent insole system with a non-
alerting watch, which recorded data but did not alert the 
patients to offload. At the baseline visit, the non-alerting 
watch was replaced with an alerting watch in the 
intervention group (single-blinded).
The insole system detected plantar pressure exceeding 
capillary perfusion pressure (>35 mm Hg) in real time, 
and integrated that pressure data over time. For every 
minute of wear, pressure readings over the previous 
15 min were analysed by the device and categorised as 
high (95–100% readings ≥35 mm Hg), medium (35–94% 
readings ≥35 mm Hg), or low (0–34% readings 
≥35 mm Hg) integrated pressure. Pressure readings were 
wirelessly transmitted to a smartwatch (SurroSense Rx, 
Orpyx Medical Technologies, Calgary, AB, Canada), where 
data were stored. For the intervention group, when 
sufficiently high-pressure time thresholds were reached at 
a specific plantar site, the smartwatch provided audiovisual 
and vibrational alerts, encouraging the patient to offload 
(figure 1). The smartwatch instructed the patient to walk 
around and cycle weight on the feet, or sit down and 
remove weight from the affected foot and check footwear 
(eg, for foreign bodies or excessively tight shoelaces). 
Once sufficient offloading occurred, the device alert 
cleared and the patient could resume normal activities.
See Online for appendix
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Patients in the intervention and control groups wore 
the same intelligent insole system. The control group 
did not receive any form of feedback via the system, 
regardless of plantar pressure data. There were no other 
differences between the intervention group and control 
group.
The pressure-feedback system was checked and 
calibrated at baseline and at every subsequent monthly 
visit, using in-house software. The insole checking and 
calibration procedure occurred at every routine monthly 
visit. For this procedure, the insoles were removed from 
the patient's shoes. The in-house software on the study 
laptop was used to confirm that the sensor sites in the 
insoles were accurately detecting a range of standard 
static pressure (25–225 mm Hg). This was done by 
applying increasing pressure increments directly to the 
insoles and reading the sensor responses from the 
software. The insoles were then calibrated to ensure that 
they accurately detected 50 mm Hg. The insoles were 
then reinserted into the patient's shoes and the same 
software was used to calibrate the sensor to a shoe-off 
scenario (ie, to account for the low pressure provided by 
the covering custom-made shoe insole on the intelligent 
insole, but not the effect of pressure from the foot in the 
shoe). In a separate procedure, every month the watch 
would be connected to the study laptop and pressure data 
would be downloaded and stored on the laptop. Patients 
were instructed to wear the system as often as possible 
for the duration of the study (ie, 1 month periods). Total 
hours of device actual wear were calculated from raw 
pressure data generated by the system and processed 
by custom scripts written in MATLAB. If the patient 
changed their footwear, the investigators refitted the 
pressure-sensing inserts and recalibrated them at the 
next site visit.
The sensor pods and smartwatch communicated using 
the ANT+ wireless communication protocol, which 
operates in the 2400–2480 MHz range. Battery life for the 
watch was 2 days (using a 350 mAh rechargeable battery) 
and for the sensor pod was 1 week (using a 80 mAh 
rechargeable battery). Patients were recommended to 
charge the sensor pods nightly to get into a regular 
routine. If connectivity between the insoles and the 
watch was lost, then the patient immediately received an 
audiovisual alert to announce that this had occurred. 
This disconnection alert occurred for all patients 
(whether in the intervention or control group). The 
patient would then be able to reconnect by tapping the 
connect screen from the watch main menu.
At the baseline visit only, demographic, medical, and 
social variables were recorded. Details of historical 
plantar ulcers were documented from podiatry or 
medical notes. A detailed foot examination identified any 
amputations and foot deformities including small 
muscle wasting, hammer or claw toes, bony prominences, 
prominent metatarsal heads, Charcot arthropathy, and 
limited joint mobility. Sensory loss for any of the 
modalities of the modified neuropathy disability score3 
classified patients with neuropathy. Cutaneous pressure 
perception was assessed using a 10 g monofilament at 
the first, third, and fifth prominent metatarsal heads on 
each foot, with the absence of sensation at any one site 
indicating neuropathy. Sudomotor dysfunction was 
assessed by the Neuropad test.25 Peripheral arterial status 
was assessed by palpating the dorsalis pedis and posterior 
tibial pulses on both feet. Quality of life was assessed 
Figure 1: SurroSense Rx intelligent insole system (Orpyx Medical Technologies, Calgary, AB, Canada)
(A) Intelligent insole system, comprising 0·6 mm flexible, pressure-sensing inserts (placed underneath the patient’s 
own orthotics or insoles) and a connecting smartwatch. (B) Sites of the pressure sensors: first metatarsal 
head [one sensor], lateral metatarsal heads [two sensors], hallux [one sensor], lateral toes [one sensor], lateral 
foot [two sensors], and heel [one sensor]. (C–E) Smartwatch screen displaying a user-friendly, visual foot map, 
highlighting areas of high pressure. The device integrates pressure data over time and uses this to generate alerts for 
the user. The user must respond to the alert by offloading the area of high pressure on their foot; the watch will 
continue to provide alerts until the pressure has been offloaded.
A B
C
E
D
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with a neuropathy and foot ulcer-specific quality of life 
instrument, the NeuroQoL.26
At the baseline and all monthly visits, examinations 
were done to identify any new plantar ulcer occurrence, 
and score callus severity at 12 distinct plantar sites per 
foot (first–fifth toes, first–fifth prominent metatarsal 
heads, midfoot, and heel). Scores were no callus (zero), 
mild callus (1), medium callus (2), and severe callus (3). 
Total callus severity scores were recorded for each foot 
at baseline and 6 months (for those in the first centre 
subcohort who reached at least 6 months in the study; 
n=26). FootSnap was used to take photographs of the 
plantar surface of each foot.24 Any issues regarding use 
of the pressure monitoring device were discussed and 
answers to adherence questions were recorded. Adverse 
events relating to the lower limb, occurring since the 
previous visit, were identified and recorded in the case 
report form after examining and interviewing the 
patient.
Outcomes
The primary outcome was foot ulcer recurrence between 
the treatment groups. A secondary outcome was adherence 
to wearing the device. Exploratory outcomes were time to 
ulceration and callus severity.
General safety monitoring was done in-house. At each 
monthly visit, patients' feet were examined, any adverse 
events possibly relating to the device were checked and 
details were documented in the case report forms.
Statistical analysis
Descriptive statistics of continuous variables were 
reported as mean (SD) or median (IQR). For categorical 
variables, proportions and frequencies were given. 
Bivariate analyses were done to compare the two study 
sites, these included χ² tests for categorical variables and 
independent samples Student’s t tests with or without 
unequal variances for the continuous variables that were 
compared.
 In an intention-to-treat analysis, Poisson regression 
models were used to compare the number of ulcers per 
patient between the treatment groups, while taking into 
account the exposure time of the patient in study (ie, to 
include those who withdrew from study early but 
remained ulcer free). Incidence rate ratios (IRR) and 
95% CIs were computed for the Poisson models and were 
adjusted separately for clinically important confounders 
identified previously, along with neuropathy disability 
score. χ² tests compared ulceration for patients, and at 
independent plantar sites, between the groups. Survival of 
ulcer recurrence was assessed between treatment groups 
with respect to the patient’s days in study and time to 
ulceration using a Kaplan-Meier curve and log-rank test. 
Cox proportional hazards models were used to calculate 
the hazard ratio (HR) and 95% CI for the active treatment 
group compared with the control group. The HRs were 
adjusted separately for study site, age, type of diabetes, 
ethnicity, and for analyses involving compliance a measure 
of device usage was included. These confounders were 
considered on the basis of their clinical importance.
Differences between the groups for total callus severity 
score (an exploratory endpoint) were tested using a 
Mann-Whitney U test.
To assess the effect of adherence to wearing the insole 
system while connected to the device, all above statistical 
tests compared ulcer outcomes between study groups 
in secondary analyses of good compliers. The good 
compliers subcohort was defined using calculations of 
total hours of device actual wear relative to the total hours 
available to the patient in the study. The data generated an 
appropriate threshold for mean hours of wear per day 
and a subcohort of 40 patients (69%) were identified as 
good compliers (threshold ≥4∙5 h wear per day). 
Treatment group differences in total hours of device 
wear (actual vs self-reported) were also tested using a 
Mann-Whitney U test.
To estimate sample size, we anticipated an 18-month 
ulcer recurrence rate of approximately 50% in the control 
group.2 A power analysis was calculated using the formula, 
2 [(Zα + Zβ)σ/∆]², where ∆=30, σ=42∙5, α level=5%, 
β level=0∙1, yielding a sample estimate of 42 patients per 
group.
Figure 2: CONSORT study flow diagram
37  at site two passed screening 
       and were randomly assigned 
12 reached 18-month follow-up  
26 included in intention-to-treat 
analysis
26 assigned to control group 
37 began 2-week wearing-in period
14 withdrew consent
7 withdrew participation
1 died
6 developed plantar foot 
ulcer(s) 
11 reached 18-month follow-up 
32 included in intention-to-treat 
analysis
32 assigned to intervention group
16 withdrew participation
1 lost to follow-up
4 developed plantar foot 
ulcer(s) 
53  at site one passed screening 
       and were randomly assigned 
53 began 2-week wearing-in period 
58 started study (35 at site one, 23 at site two) 
18 withdrew consent 
54 patients screened at site one 
1 ineligible 
40 patients screened at site two
3 ineligible 
Articles
e313 www.thelancet.com/digital-health   Vol 1   October 2019
A p value of less than 0∙05 was considered statistically 
significant. All analyses were intention to treat, and were 
done using Stata, version 14.
An independent data safety monitoring board was 
not used because there were no recommendations or 
requirements for one from the ethics committees or 
governance bodies. This trial is registered with ISRCTN, 
ISRCTN05585501, and is closed to accrual and complete.
Role of the funding source
The funder of the study (Diabetes UK for years 1–3) had 
no role in the study design, data collection, analysis and 
interpretation of the data, in the writing of the report or in 
the decision to submit the paper for publication. Orpyx 
Medical Technologies (funder of year 4) provided the 
insole systems for the study and technical support for the 
insole systems, but also had no role in the study design, 
data collection, analysis and interpretation of the data, or 
the writing or submission of the report. Years 1–3 relate to 
the funding period of the first 3 years of the research 
project, and includes the period of study site training 
and initiation, study start-up and recruitment, study 
completion, and data capture. Year 4 relates to the period 
of statistical analyses and manuscript preparation. CAA, 
KEC, and PF had access to all data. CAA and NDR were 
responsible for the decision to submit the Article.
Control 
group (n=26)
Intervention 
group (n=32)
Age, years 67·1 (9·6) 59·1 (8·5)
Sex
Female 3 (11%) 4 (12%)
Male 23 (89%) 28 (88%)
Site 1 16 (61%) 19 (59%)
Type 2 diabetes 22 (85%) 23 (72%)
Diabetes duration, years 21·2 (10·7) 22·2 (14·3)
Ethnicity
White 21 (81%) 28 (88%)
Asian 4 (15%) 1 (3%)
Black or mixed 1 (4%) 3 (9%)
Glycated 
haemoglobin A1c, mmol/mol*†
58 (51–67),
7·5 (5·9–9·7)
66 (54–81),
8·2 (5·6–13·3)
Height, m 1·76 (0·09) 1·79 (0·10)
Weight, kg‡ 95·7 (16·8) 102·1 (18·9)
Body-mass index, kg/m2‡ 30·9 (4·8) 31·9 (5·8)
Quality of life measure (NeuroQoL)§
Pain 1·88 (0·76) 2·00 (0·88)
Reduced sensation/feet 2·57 (1·49) 3·40 (1·32)
Unsteadiness 2·66 (1·48) 2·47 (1·32)
ADL-restrictions 2·35 (1·39) 2·78 (1·58)
Emotional burden 2·61 (1·35) 3·25 (1·13)
NDS
Minimal (NDS 0–2) 2 (8%) 2 (6%)
Mild (NDS 3–5) 5 (19%) 4 (13%)
Moderate (NDS 6–8) 7 (27%) 12 (38%)
Severe (NDS 9 or 10) 12 (46%) 14 (44%)
Abnormal 10 g Semmes-Weinstein monofilament
Left 19 (76%) 29 (91%)
Right 17 (68%) 31 (97%)
Neuropad, abnormal test¶ 21 (96%) 24 (92%)
Previous toe amputations, left foot
Hallux 0 3 (10%)
Second to fifth toe 2 (8%) 1 (3%)
Previous toe amputations, right foot
Hallux 1 (4%) 0
Second to fifth toe 1 (4%) 2 (6%)
(Table 1 continues in next column)
Control 
group (n=26)
Intervention 
group (n=32)
(Continued from previous column)
Foot Deformity Score*||
Left 1·0 (0·0–2·5) 2·0 (0·0–3·0)
Right 1·5 (0·75–3·0) 1·5 (0·0–3·0)
Location of most recently healed plantar foot ulcer, left
None 12 (46%) 8 (25%)
Hallux, second to fifth toes 7 (27%),
6 (23%)
9 (28%),
5 (16%)
First MTH, second to fifth MTH 0, 
0
2 (6%), 
6 (19%)
Midfoot 1 (4%) 1 (3%)
Heel 0 1 (3%)
Location of most recently healed plantar foot ulcer, right
None 7 (27%) 10 (31%)
Hallux, second to fifth toes 5 (19%),
4 (15%)
6 (19%), 
2 (6%)
First MTH, second to fifth MTH 4 (15%), 
1 (4%)
5 (16%),
4 (13%)
Midfoot 3 (12%) 5 (16%)
Heel 2 (8%) 0
Palpable dorsalis pedis pulse
Left** 19 (79%) 26 (87%)
Right†† 20 (83%) 23 (79%)
Palpable posterior tibial pulse
Left** 20 (83%) 21 (70%)
Right†† 20 (83%) 20 (69%)
Data are n (%) or mean (SD), unless otherwise stated. NeuroQoL subscale scores 
range from 1 (never) to 5 (all the time); high score equates to more impairment. 
Abnormal monofilament was defined as the inability to feel pressure sensation at 
any one of four plantar sites on both feet (hallux, first, third, and fifth metatarsal 
head). Foot Deformity Score comprised a total of abnormal scores (1) for each of 
the following per foot: hammer or claw toes, prominent metatarsal heads, small 
muscle wasting, bony prominences, Charcot, or limited joint ability as determined 
by prayer sign. ADL=activities of daily living. NDS=Neuropathy Disability Score. 
MTH=metatarsal head. *Data are median (IQR). †24 patients with data in the 
control group; 28 patients with data in the intervention group. ‡31 patients with 
data in the intervention group. §17 patients with data in the control group; 
17 patients with data in the intervention group. ¶22 patients with data in the 
control group; 30 patients with data in the intervention group. ||Scored from 
1 to 6. 22 patients with data in the control group; 28 with data in the intervention 
group. **24 patients with data in the control group; 30 patients with data in the 
intervention group. ††24 patients with data in the control group; 29 patients 
with data in the intervention group.
Table 1: Patients' baseline characteristics
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Results
Between March 18, 2014, and Dec 20, 2016, of 94 patients 
who were screened, 90 patients were recruited and 
consented to study (figure 2). Patients who withdrew 
consent before the baseline visit (n=32) were not different 
in age, diabetes duration, glycated haemoglobin A1c 
(HbA1c), BMI, neuropathy severity, foot deformities, or 
psycho logical status, compared with those who continued 
in the study (n=58). Patients who started the study at 
baseline and withdrew before 18 months for reasons other 
than the development of diabetic foot ulcer (n=23) were 
not different for these characteristics compared with all 
other patients who started the study at baseline (n=35). 
Patients who started the study and withdrew before 
18 months, but did not develop diabetic foot ulcer, showed 
no difference in time in study, when the intervention 
(n=16) and control (n=7) groups were compared (median 
221 days [IQR 98–376] vs 145 [57–217], respectively; p=0∙31).
The baseline characteristics of the intention-to-treat 
patients are shown in table 1. Although most charac-
teristics were similar between groups, the intervention 
group was younger, had higher HbA1c, greater ethnic 
diversity, and a higher proportion of type 1 diabetes than 
the control group. Use of off-the-shelf versus custom-
made shoes was not different between the intervention 
group (eight [42%] of 19 and 11 [58%] of 19, respectively) 
and control group (seven [44%] of 16 and nine [56%] of 16, 
respectively) for those who started the study (site 1 only; 
n=35). Adverse events relating to the lower limb recorded 
at follow-up visits are given in table 2.
For the subgroup of patients in the intervention group 
from site 1 (n=19) who recorded their daily alerts and 
subsequent offloading behaviour, a mean of 12 self-
reported audiovisual alerts (SD 5) were received per day 
over the study period. 18 patients (95%) described 
sometimes receiving alerts while in a static position (ie, 
sitting, driving, or standing) then stopping the alert by 
changing the position of or offloading the foot (or both); 
17 patients (89%) described sometimes receiving alerts 
while in a static position and then stopping the alert by 
walking around; only two patients (11%) described 
sometimes receiving alerts while walking and then 
stopping the alerts by sitting down or offloading.
During a total of 597 follow-up visits, 14 new plantar 
foot ulcers were identified. All ulcer sites occurred on the 
forefoot (great toe n=5; second toe n=1; third toe n=2; 
first metatarsal head [MTH] n=3; third MTH n=1; 
fourth MTH n=1; fifth MTH n=1). Ulcers in the inter-
vention group were Texas classification grades 1A–3C, 
with one person requiring antibiotics; ulcers in the 
control group were Texas classification grades 1A–2B, 
with one person requiring antibiotics.
In total, ten ulcers from 8638 person-days from six 
patients were recorded in the control group, and four 
ulcers from 11 835 person-days from four patients were 
recorded in the intervention group. Overall, ten (17%) of 
58 patients ulcerated (seven had a single ulcer site on one 
foot; one had a single ulcer site on both feet; one had 
two ulcer sites on one foot; and one had two ulcer sites on 
the left foot, and one ulcer site on the right foot). There 
was no difference between the groups for patients who 
ulcerated (six of 26 [control group] vs four of 32 [intervention 
group]; p=0∙29, χ² test). However, individual plantar sites 
ulcerated more often in the control group (ten of 416) than 
in the intervention group (four of 512; p=0∙047).
In survival analyses, the Kaplan-Meier curve and log-
rank test showed no significant difference between 
treatment groups for time to ulceration. At 18 months, 
68% of patients in the control group and 78% of patients 
in the intervention group were ulcer-free (p=0∙30; 
figure 3). Cox proportional hazards regression ratio was 
unchanged between intervention group versus control 
group (0∙51, 95% CI 0∙15–1∙83; p=0∙30).
Poisson regression analyses compared the number of 
ulcers per patient between the treatment groups and 
considered study exposure time. The analysis showed 
a 71% reduction in the risk of re-ulceration in the 
intervention group compared with the control group 
(IRR 0∙29, 95% CI 0∙09–0∙93; p=0∙037). The 95% CI is 
wide because of the low number of events, and should 
therefore be interpreted with caution.
Based on device data, patients in the intervention 
group wore the device for a median of 539∙0 h 
(IQR 190·0–1488·5), compared with 763∙4 h 
(188∙4–1461∙4) for the control group (p=0∙85). The 
control group wore the device for 6∙9 h per day (4∙5–8·9) 
versus 6∙1 h per day (4∙3–7∙6) for the intervention group 
(p=0∙22).
In the first centre subcohort (n=34), the median self-
reported estimates of total hours that the device was worn 
in study were not different between the intervention and 
control groups (1555 h, IQR 649∙8–2528∙0 vs 1370∙5 h, 
406∙8–1984∙5, respectively; p=0∙47). The median self-
reported number of hours the device was worn per day 
was 4∙3 h (2∙9–5∙8) in the control group and 5∙2 h 
(2∙9–7∙7) in the intervention group (p=0∙56). Spearman’s 
rank correlation showed a positive correlation between 
self-reported and actual hours worn per day (r=0∙59, 
p=0∙001) and total hours worn (r=0∙88, p<0∙0001).
Based on device data, 18 patients were identified as 
wearing the device for less than a mean of 4∙5 h per day 
Control 
group (n=26)
Intervention 
group (n=32)
Charcot changes 0 2 (6%)
Pain in lower back, hip, or knee 8 (31%) 4 (13%)
Significant falls 3 (12%) 3 (9%)
Trauma to knee, foot, ankle, toes 13 (50%) 11 (34%)
Superficial dorsal surface foot ulcer 2 (8%) 0
Infected toenail 3 (12%) 2 (6%)
Total 29 22
Table 2: Adverse events relating to the lower limb
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during the study, calculated using a cutoff ratio of 25 for 
total hours in study per total hours worn; they were 
rejected from all following analyses for good compliers 
only (n=40; intervention group n=22, control group 
n=18).
In a survival analysis, using Cox proportional hazards 
regression model, the hazard ratio for the intervention 
versus control groups (0∙25, 95% CI 0∙05, 1∙24; p=0∙090) 
showed no significant effect of intervention on time to 
ulceration in patients who ulcerated. Adding age, 
diabetes type, and ethnicity into the model did not 
significantly affect the hazard ratio.
Of the good compliers, ten ulcers from 6308 person-
days were recorded in the control group and two ulcers 
from 9077 person-days were recorded in the intervention 
group. In exploratory Poisson regression analysis, there 
was a difference in the IRR between the intervention and 
control groups (0∙14, 95% CI 0∙03–0∙63; p=0∙011), with 
patients in the intervention group expected to have an 
86% reduction in the risk of re-ulceration rate (0∙14 times 
lower) than patients in the control group. Addition of 
other covariates into the model had little effect on the IRR.
Total callus severity score was similar between the 
groups (intervention group n=13, control group n=13) at 
the baseline visit (median 3 [IQR 1–11∙5] vs 4 [2–7], 
respectively; p=0∙96). The control group showed no 
difference in increased callus severity score after 
6 months (12 [3·0–12∙5]) when compared with the 
intervention group (5 [1·0–8∙5]; p=0∙20). The absolute 
change in callus severity score (the greater the positive 
score, the worse the total callus severity over time) 
from baseline to 6 months was increased by a score 
of 5·0 (IQR 1∙5–8∙5) in the control group and by a score 
of 1·0 (0·0–5·0) in the intervention group (p=0∙13). The 
absolute change in callus severity score from baseline to 
6 months was greater for patients who developed a new 
plantar ulcer (n=6) compared with those who did not 
ulcerate (n=20; 6∙5 [IQR 4∙0–8∙3] vs 2·0 [0∙0–4∙8], 
respectively; p=0∙040). 
For the intervention group patients who self-recorded 
their daily alerts (n=19), the mean number of alerts per 
day positively correlated with total feet callus severity 
score after 6 months (r=0∙78, p=0∙038).
Discussion
In this prospective, randomised, proof-of-concept study, 
we have shown a reduction in the recurrence of diabetic 
foot ulcer sites by use of an innovative insole system 
providing continuous plantar pressure feedback and 
encouragement to offload throughout daily life. In an 
intention-to-treat analysis, diabetic foot ulcer site 
recurrence over an 18-month follow-up period was 
reduced by 71% in the intervention group. In secondary 
analyses, diabetic foot ulcer recurrence was reduced by 
86% in the intervention group when comparing groups 
compliant with wearing the connected device on a daily 
basis. Time to ulceration was also extended in compliant 
users of the active device. However, we found no 
significant effect of the system on reducing the number 
of patients who had re-ulceration. We emphasise that 
these results should be interpreted with caution due to 
the wide CIs and borderline statistical significance in this 
relatively small study.
The novelty of this study is two-fold. First, the system 
functionality is innovative, measuring cumulative 
pressure applied over time, whereas the majority of 
existing literature is orientated towards capturing instan-
taneous peaks in high pressure.2,11,12 Furthermore, the 
intervention itself (used in conjunction with a patient’s 
custom-made insoles) is self-directed, dynamic offloading 
involving a chain of events: a smartwatch alert occurred 
when the pressure threshold of more than 35 mm Hg is 
exceeded over time, the alert was then acknowledged by 
the patient, and the patient then was able to offload 
plantar pressure to stop the alert.
A high proportion (>75%) of ulcers recurred within 
6 months, showing the high-risk status of the patients 
Figure 3: Kaplan-Meier plots on cumulative survival of plantar foot ulcer 
recurrence
(A) Intention-to-treat population (n=58). (B) Patients who were highly 
compliant in wearing their intelligent insole system (n=40). 
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and the frequency of re-ulceration following previous 
complete healing.2 The frequency of ulcer recurrence 
over 18 months in the control group (23%) was similar to 
that in a separate foot ulcer prevention trial (17%);7 
however, these are relatively conservative percentages 
for a high-risk cohort that are normally estimated at 
approximately 40% per annum.2 This finding might 
reflect the protective effect of regular foot care visits at 
monthly intervals throughout our study, in addition to 
the ongoing effect of provision of National Institute 
for Health and Care Excellence guidelines on the 
management of the diabetic foot in the UK.27 The two 
study sites had dedicated diabetic foot care teams with 
patient access to podiatry services with multidisciplinary 
care pathways and protocols for managing diabetic foot 
problems, which culminates in better lower limb 
outcomes in the UK.28 The availability of regional diabetic 
foot care meant that we had a robust control group. In 
addition, provision of the non-alerting system to patients 
in the control group, as opposed to following their 
diabetic foot ulcer natural history, enabled us to show 
efficacy of the audiovisual feedback alerts for a reduction 
of diabetic foot ulcers. Our study design accounted for 
potential confounding variables of frequency of patient 
contact, direction of attention to foot health, and any 
potential placebo effect of the device. However, the high 
drop-out rate and lower number randomly assigned than 
expected is likely to have attenuated the beneficial effect 
of the intervention.
The majority (95%) of intervention group patients self-
reported alerts occurring while in static activities; 
eg, sitting working at a computer (with feet tucked under 
a chair), driving, or standing still for prolonged periods, 
with regular movement of foot positions to break bouts of 
sustained pressure successfully stopping the alerts. Only 
a minority (11%) described ever receiving alerts while 
walking. These self-reports are surprising, because 
current literature on diabetic foot ulcer risk features 
mainly high pressures sustained during normal gait. 
However, these self-reports are consistent with con-
clusions from two studies25,29 and might justify revisiting 
the nature of activities believed to be high risk for 
ulceration in future studies.
Compliance to wearing the device was calculated from 
device data obtained only during periods when the in-
shoe device was worn in the shoes while wirelessly 
connected to the smartwatch. Continuous recordings 
from the intelligent insoles allowed accurate assessment 
of patients who were defined as good compliers, 
removing those who wore the device for less than a mean 
of 4·5 h per day; ie, not receiving sufficient daily plantar 
pressure feedback offloading advice for adequate benefit. 
Calculation of hours of wear per day did not include 
periods when the patient was wearing shoes with the 
insoles, but without connection to the smartwatch, nor 
periods of wearing the watch only without insoles being 
in the shoes. Adherence to treatment has been shown 
to be especially important in clinical trials of plantar 
ulcer healing and recurrence prevention, with adherent 
patients showing significantly improved healing times 
and fewer ulcer events than those who did not.6,8,30 
Throughout the study, adequate adherence meant that 
patients received high-pressure alerts and were provided 
with the opportunity to take the necessary action to 
offload the pressure, which is the most effective treat-
ment for diabetic foot ulcer prevention reported to date.31 
Reasons for non-adherence included low perceived 
aesthetic value of the device, or reticence to manage the 
smartwatch technology, or both.
There are several potential mechanisms for acceptable 
adherence. Patients were given detailed foot care education 
and were trained in the use of the device to offload 
pressure effectively. Continuous education is recom-
mended to achieve ulcer prevention,2 which was provided 
on a daily basis by the alerting smartwatch. Additionally, 
patients were empowered to self-monitor and were likely 
to have had a high level of self-management using 
this technology. Good self-management has been shown 
to reduce ulcer incidence in high-risk patients who 
successfully home-monitored foot skin temperatures and 
sought foot care when temperatures deviated from a 
specified threshold between feet.30,32 This finding illustrates 
a similar concept of the effectiveness of patient empower-
ment through targeted technology.
Other exploratory evidence supporting the beneficial 
effect of intervention was protection against progressive 
development of plantar callus formation over the first 
6 months, with callus severity worsening in those who 
re-ulcerated compared with those who did not. This 
finding substantiates the direct effect of sustained 
plantar pressures on callus development and diabetic 
foot ulcer development in such high-risk patients. 
Plantar callus involving hyperkeratosis is caused by 
excessive mechanical loading and increased plantar 
pressures due to foot deformities, limited joint mobility, 
sensory and autonomic dysfunction,33,34 and is among 
one of the strongest predictors of foot re-ulceration.35 
These results should be interpreted with caution, but 
might indicate a mechanism for device efficacy; that is, 
when alerts were received in response to abnormally 
high cumulative plantar pressure loading, patients off-
loaded or adjusted their weight-bearing activity levels, or 
both, reducing callus formation and, ultimately, diabetic 
foot ulcers.
The intention-to-treat analysis was underpowered 
because of higher than expected attrition rate for patients 
who consented to study, but withdrew after the wearing-
in period, before their baseline visit. There were four 
main reasons provided for high drop-out before the 
baseline visit. The first of these reasons is the broad 
inclusion criteria used to recruit sufficient patients 
with previously healed diabetic foot ulcer, because 
these patients comprise only approximately 3% of the 
general diabetes community.2 The high prevalence of 
Articles
e317 www.thelancet.com/digital-health   Vol 1   October 2019
comorbidities (coronary artery disease, retinopathy, and 
nephropathy) in these high-risk patients often resulted 
in withdrawal because of too many other hospital 
appointment commitments. The second reason relates 
to the device proving challenging for some individuals, 
with patients describing problems engaging with the 
smartwatch technology. The device required charging 
every other day and connecting to the smartwatch each 
time the shoes were put on (after taking them off). 
Variables that might have affected how patients dealt 
with these challenges (but were not assessed) include 
cognitive function, eyesight, manual dexterity, and 
family or friend assistance in trouble-shooting. Third, 
some patients’ custom-made shoes were too deep to 
allow the device to fit optimally, and this was a reason for 
some of the dropouts observed post-randomisation. 
Finally, some patients reported a reluctance to commit to 
wearing only lace-up or velcro shoes for up to 18 months, 
realising that they would prefer to sometimes wear slip-
on shoes or sandals, especially during summer months. 
All of these observations should be useful for the future 
targeting of appropriate cohorts to benefit from using 
active-feedback insole systems.
Other study limitations included the continued 
withdrawal of intention-to-treat patients after baseline, 
with similar reasons to those for prebaseline withdrawals. 
Withdrawing patients in the intervention and control 
groups used the device for substantial, similar periods. 
Interestingly, no-one in the intervention group withdrew 
because of frequency of the alerts; therefore, the mean 
12 (SD 5) self-reported audiovisual alerts received per day 
over the study period might be considered a tolerable 
level for successful intervention. Although the in-shoe 
system was considered to have a very low risk of potential 
harm to patients, the lack of an independent data safety 
monitoring board is a limitation of our study. We 
recommend that future, long-term studies should use a 
data safety monitoring board.
Standardised shoes were not used by study patients 
because all patients had a high risk of developing ulcers, 
with most using their own prescription footwear for 
clinical necessity and patient safety. Rather than a 
limitation, having individual bespoke footwear across all 
patients is beneficial, because all patients have slightly 
different foot deformities or shapes, and the footwear 
creates a certain commonality across all patients in terms 
of accommodating bony prominences and reducing all 
potential for focal zones of high pressure.
We recorded plantar pressure at 8 Hz, whereas foot 
pressure measurement in the laboratory is normally 
done at a minimum of 50 Hz to identify peak pressures 
occurring for very short durations.8,16,17 This 8 Hz sampling 
frequency is more than adequate for measuring sustained 
levels of high, but not peak, pressures, which underlies 
the premise on which this prevention study was based. 
Diabetic foot ulcers can develop when less pressure (than 
peak) is applied over a long period, and it is possible for 
irreversible tissue damage to occur within 1–2 h at these 
less-than-peak, sustained pressures.15
In conclusion, we have shown the incidence of recurrent 
diabetic foot ulcer can be reduced over 18 months in high-
risk diabetic patients using an innovative intelligent insole 
system, providing continuous plantar pressure feedback 
and encouragement to offload throughout daily life. Key 
elements to the success of this trial have been adequate 
training of patients in the use of the intelligent insole 
technology and patients’ adherence to wearing the device 
on a daily basis for at least 6 months. We recommend that 
future randomised controlled trials test the efficacy and 
cost-effectiveness of this technology in the wider diabetic 
at-risk neuropathic community for ulcer prevention.
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